Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis
Javier Vázquez-Bourgon,
Víctor Ortiz-García de la Foz,
Irene Suarez-Pereira,
Paula Iruzubieta,
María Teresa Arias-Loste,
Esther Setién-Suero,
Rosa Ayesa-Arriola,
Marcos Gómez-Revuelta,
Javier Crespo,
Benedicto Crespo Facorro
Affiliations
Javier Vázquez-Bourgon
Department of Psychiatry, University Hospital de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Spain; Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, Santander, Spain; Corresponding author. Department of Psychiatry, University Hospital de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain.
Víctor Ortiz-García de la Foz
Department of Psychiatry, University Hospital de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Spain
Irene Suarez-Pereira
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Spain; Neuropsychopharmacology & Psychobiology Research Group, University of Cádiz, Instituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz, INiBICA, Edificio “Andrés Segovia”, Cádiz, Spain
Paula Iruzubieta
Gastroenterology and Hepatology Unit, University Hospital de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain
María Teresa Arias-Loste
Gastroenterology and Hepatology Unit, University Hospital de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain
Esther Setién-Suero
Department of Psychiatry, University Hospital de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Spain; Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, Santander, Spain
Rosa Ayesa-Arriola
Department of Psychiatry, University Hospital de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Spain; Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, Santander, Spain
Marcos Gómez-Revuelta
Department of Psychiatry, University Hospital de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Spain; Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, Santander, Spain
Javier Crespo
Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, Santander, Spain; Gastroenterology and Hepatology Unit, University Hospital de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain
Benedicto Crespo Facorro
Department of Psychiatry, University Hospital de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Spain; Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, Santander, Spain
The presented article describes data from secondary analyses, related to the research article entitled “Cannabis consumption and Non-Alcoholic Fatty Liver Disease. A three years longitudinal study in first episode non-affective psychosis patients” [1]. We present detailed data regarding the socio-demographic and baseline clinical characteristics of a sample of 390 drug-naïve patients with a first episode of non-affective psychosis, and the differences between cannabis users and non-users in those characteristics. Tables also show the results from cross-sectional and longitudinal statistical analyses exploring the relation between cannabis consumption and liver function, after excluding those patients with hazardous alcohol drinking. Keywords: Cannabis, Psychosis, Liver, Liver steatosis, NAFLD, Antipsychotic treatment, Mental health
